28 results
425
EX-99.1
PYXS
Pyxis Oncology Inc
24 May 23
Business combination disclosure
4:55pm
formulated a diverse leadership team with a proven track record of success, that strongly positions the organization to deliver meaningful impact
425
APGN
Apexigen Inc
24 May 23
Business combination disclosure
7:05am
with the transaction.
Post-Closing Operations and Leadership
Effective as of the closing of the transaction, the combined company will trade … on Nasdaq under the ticker symbol “PYXS” and the existing Pyxis Oncology leadership team will continue to be responsible for all executive positions
8-K
EX-99.1
APGN
Apexigen Inc
24 May 23
Pyxis Oncology to Acquire Apexigen
7:02am
with the transaction.
Post-Closing Operations and Leadership
Effective as of the closing of the transaction, the combined company will trade on Nasdaq under … the ticker symbol “PYXS” and the existing Pyxis Oncology leadership team will continue to be responsible for all executive positions, including Lara S
424B3
APGN
Apexigen Inc
10 Apr 23
Prospectus supplement
4:03pm
believe Mr. Cross is qualified to serve on the Board because of his substantial experience in executive leadership roles at various life sciences … extensive experience in various leadership roles including as chief executive officer in the life sciences and biotechnology industries.
Gordon Ringold
424B3
APGN
Apexigen Inc
10 Apr 23
Prospectus supplement
4:02pm
in executive leadership roles at various life sciences companies, and his extensive knowledge of strategic financial management and corporate … . Karson is qualified to serve on the Board because of her extensive experience in various leadership roles including as chief executive officer
POS AM
t2mmh5q8maxiet ckve
4 Apr 23
Prospectus update (post-effective amendment)
4:24pm
POS AM
pi7 bs9m0i
4 Apr 23
Prospectus update (post-effective amendment)
4:23pm
424B3
nykra8btqk7kprj
9 Sep 22
Prospectus supplement
4:40pm
424B3
imenz y5q0gbjco24
9 Sep 22
Prospectus supplement
4:38pm
425
3yhs2l7l coyt3h630k
29 Jun 22
Business combination disclosure
4:39pm
425
q4wzwxfrugl46hk
8 Jun 22
Business combination disclosure
5:25pm
425
lnflk alqz
9 May 22
Business combination disclosure
5:07pm
425
rdu 0fsh284pwllx
22 Apr 22
Business combination disclosure
4:41pm
S-4
zq986d3qyh6yw4kc0ww
8 Apr 22
Registration of securities issued in business combination transactions
6:37pm
10-K
wtyr3prf
7 Apr 22
Annual report
5:13pm
DEF 14A
3bqzzud7dv t8ydg
28 Mar 22
Definitive proxy
5:30pm